KalVista Pharmaceuticals, Inc.KALVNASDAQ

Revenue (LTM)

Net Income (LTM)

$-183M

-44.9% YoY

Free Cash Flow

$-153M

Revenue CAGR (5Y)

—

—Marginsstable

FCF($0.2B)

Unprofitable

Metric	Apr 21	Apr 22	Apr 23	Apr 24	Apr 25
Revenue	0	0	0	0	0
Gross Profit	-41	0	0	-86	0
Operating Income	-58	-97↓66.8%	-111↓14.8%	-140↓26.7%	-188↓33.9%
Net Income	-46	-82↓78.1%	-93↓12.8%	-127↓36.3%	-183↓44.9%
EBITDA	-57	-81↓40.7%	-94↓16.9%	-134↓42.3%	-173↓29.1%
EPS Diluted	-2.33	-3.36↓44.2%	-3.33↑0.9%	-3.44↓3.3%	-3.69↓7.3%

Metric	Apr 21	Apr 22	Apr 23	Apr 24	Apr 25
Cash & Equivalents	51	31↓39.3%	56↑83.0%	32↓43.5%	99↑210.3%
Total Current Assets	264	194↓26.7%	172↓11.0%	226↑31.0%	242↑7.1%
Total Assets	272	204↓25.0%	183↓10.1%	235↑28.5%	251↑6.5%
Total Current Liabilities	10	12↑18.4%	15↑29.9%	23↑51.7%	45↑98.0%
Total Liabilities	15	19↑26.8%	22↑18.0%	29↑30.0%	155↑439.1%
Total Equity	257	185↓28.0%	161↓13.0%	207↑28.3%	95↓53.8%
Total Debt	6	8↑38.6%	8↑0.5%	7↓11.1%	6↓13.8%
Net Debt	-45	-23↑49.5%	-48↓112.9%	-24↑49.0%	-92↓277.3%

Metric	Apr 21	Apr 22	Apr 23	Apr 24	Apr 25
Operating Cash Flow	-30	-78↓159.0%	-75↑3.7%	-89↓18.6%	-153↓71.4%
Capital Expenditure	-0	-1↓1035.4%	-1↓28.5%	-0↑63.0%	-0↑2.0%
Free Cash Flow	-30	-79↓161.3%	-76↑3.3%	-90↓17.3%	-153↓71.0%
Stock-Based Comp	7	0	10	22↑120.9%	12↓43.9%
Net Change in Cash	35	-20↓157.1%	26↑228.4%	-24↓195.9%	100↑508.3%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance